<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-599
Date of Submission: 2025-07-15

This report was submitted by a Nurse from Myers Inc Medical Center concerning patient ANON-PX-1502. The subject is a 71-year-old other with a significant medical history including hypertension, seasonal allergies. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Atorvastatin (Statin) administered via the Topical route at a dosage of 191mg, initiated on 2025-05-29 for Hypercholesterolemia and discontinued on 2025-06-12; Omeprazole administered via the Intravenous route at a dosage of 57mg, initiated on 2025-05-29 for Gastroesophageal reflux disease and discontinued on 2025-06-12.

On approximately 2025-06-11, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Anaphylaxis, Stevens-Johnson syndrome. The Anaphylaxis was classified as Life-threatening in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. The Stevens-Johnson syndrome was classified as Severe in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Force third identify economic return information thing. Five a investment against attention.</data>
report_id: ADR-2025-599
report_date: '2025-07-15'
patient_details:
  patient_id: ANON-PX-1502
  gender: Other
  relevant_history:
  - hypertension
  - seasonal allergies
  age_at_reaction: 71
suspected_drugs:
- drug_name: Atorvastatin
  dosage: 191mg
  route_of_administration: Topical
  start_date: '2025-05-29'
  indication_for_use: Hypercholesterolemia
  drug_class: Statin
  end_date: '2025-06-12'
- drug_name: Omeprazole
  dosage: 57mg
  route_of_administration: Intravenous
  start_date: '2025-05-29'
  indication_for_use: Gastroesophageal reflux disease
  end_date: '2025-06-12'
adverse_reactions:
- symptom_name: Anaphylaxis
  onset_date: '2025-06-11'
  severity: Life-threatening
  outcome: Not Recovered
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-06-11'
  severity: Severe
  outcome: Recovering
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
reporting_facility: Myers Inc Medical Center
reporter_type: Nurse
notes: Force third identify economic return information thing. Five a investment against
  attention.
